

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM834911

<b>SUBMISSION TYPE:</b>	RESUBMISSION		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>RESUBMIT DOCUMENT ID:</b>	900795517		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Clinical Research Holdings, LLC		08/21/2023	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	FEAC Agent, LLC		
<b>Street Address:</b>	500 Boylston Street		
<b>Internal Address:</b>	Suite 1250		
<b>City:</b>	Boston		
<b>State/Country:</b>	MASSACHUSETTS		
<b>Postal Code:</b>	02116		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3774386	ACCEL CLINICAL SERVICES	
<b>Registration Number:</b>	5435841	ACCEL RESEARCH SITES	
<b>Serial Number:</b>	97915045	ACCEL RESEARCH SITES NETWORK	
<b>Serial Number:</b>	97915043	A	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2024083141		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2024083141		
<b>Email:</b>	jean.paterson@cscglobal.com		
<b>Correspondent Name:</b>	CSC		
<b>Address Line 1:</b>	1090 Vermont Avenue, NW		
<b>Address Line 4:</b>	Washington, D.C. 20005		
<b>NAME OF SUBMITTER:</b>	Jean Paterson		
<b>SIGNATURE:</b>	/jep/		
<b>DATE SIGNED:</b>	08/28/2023		

**Total Attachments: 5**

source=8-22-2023 Clinical\_Research\_Holdings\_LLC\_\_TM#page1.tif

source=8-22-2023 Clinical\_Research\_Holdings\_LLC\_\_TM#page2.tif

source=8-22-2023 Clinical\_Research\_Holdings\_LLC\_\_TM#page3.tif

source=8-22-2023 Clinical\_Research\_Holdings\_LLC\_\_TM#page4.tif

source=8-22-2023 Clinical\_Research\_Holdings\_LLC\_\_TM#page5.tif

## TRADEMARK SECURITY AGREEMENT

**Trademark Security Agreement**, dated as of August 21, 2023 (this “**Trademark Security Agreement**”), by Clinical Research Holdings, LLC, a Delaware limited liability company (the “**Grantor**”), in favor of FEAC Agent, LLC, in its capacity as administrative agent and collateral agent pursuant to the Credit Agreement (as defined in the Security Agreement, defined below) (in such capacity, the “**Administrative Agent**”).

### WITNESSETH:

WHEREAS, the Grantor are party to that certain Security Agreement, dated as of December 20, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Security Agreement**”), in favor of the Administrative Agent pursuant to which the Grantor are required to execute and deliver this Trademark Security Agreement;

NOW, THEREFORE, in consideration of the premises and to induce the Administrative Agent, for the benefit of the Secured Parties, to enter into the Credit Agreement, the Grantor hereby agree with the Administrative Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Security Agreement and used herein have the respective meanings given to them in the Security Agreement and the Credit Agreement.

SECTION 2. Grant of Security Interest in Trademark Collateral. The Grantor hereby collaterally assigns and pledges to the Administrative Agent, for the benefit of the Secured Parties, and hereby grants to the Administrative Agent for the benefit of the Secured Parties a continuing security interest in all of its right, title and interest in, to and under all the following Collateral (excluding any Excluded Assets) of the Grantor: (a) the Trademarks of the Grantor listed on Schedule I attached hereto, (b) all goodwill connected with the use of and symbolized thereby, (c) all income, fees, royalties, damages, claims and payments now and hereafter due and/or payable thereunder or with respect thereto including damages and payments for past, present or future breach or violations thereof, (d) all rights to sue for past, present and future infringements, dilutions or other violations thereof, and (e) all other rights, priorities, and privileges accruing thereunder or pertaining thereto.

SECTION 3. The Security Agreement. The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Administrative Agent pursuant to the Security Agreement and the Grantor hereby acknowledge and affirm that the rights and remedies of the Administrative Agent with respect to the security interest in the Trademarks made and granted hereby are more fully set forth in the Security Agreement, the terms of which are incorporated herein by reference. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

SECTION 4. Termination. Upon the termination of the Security Agreement in accordance with Section 6.11 thereof, the Administrative Agent shall, at the expense of the Grantor, execute, acknowledge, and deliver to the Grantor an instrument in writing in recordable

form releasing the lien on and security interest in the Trademarks under this Trademark Security Agreement.


SECTION 5. Counterparts. This Trademark Security Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery by telecopier, .pdf or other electronic imaging means of an executed counterpart of a signature page to this Trademark Security Agreement shall be effective as delivery of an original executed counterpart of this Trademark Security Agreement.

SECTION 6. Governing Law. The terms of Sections 10.15 and 10.16 of the Credit Agreement with respect to governing law, submission of jurisdiction, venue and waiver of jury trial are incorporated herein by reference, *mutatis mutandis*, and the parties hereto agree to such terms.

*[Remainder of Page Intentionally Left Blank; Signature Pages Follow]*

**Grantor:**

**CLINICAL RESEARCH HOLDINGS, LLC**

DocuSigned by:  
  
By: \_\_\_\_\_  
Name: Carlos Orantes  
Title: President and Chief Executive Officer

[SIGNATURE PAGE TO TRADEMARK SECURITY AGREEMENT]

**TRADEMARK  
REEL: 008179 FRAME: 0062**

FEAC Agent, LLC, as the Administrative Agent

By: 

Name: Michelle Handy

Title: Managing Director

[SIGNATURE PAGE TO TRADEMARK SECURITY AGREEMENT]

**TRADEMARK**  
**REEL: 008179 FRAME: 0063**

**SCHEDULE I  
TRADEMARKS**

<u>Owner</u>	<u>Registration No.</u>	<u>Registration Date</u>	<u>Filing Date</u>	<u>Mark</u>
Clinical Research Holdings, LLC	RN: 3,774,386 SN: 77/789,409	April 13, 2010	July 24, 2009	ACCEL CLINICAL SERVICES\  Disclaimer: "CLINICAL SERVICES"
Clinical Research Holdings, LLC	RN: 5,435,841 SN: 86/955,371	April 3, 2018	March 28, 2016	ACCEL RESEARCH SITES  Disclaimer: "RESEARCH SITES"
Clinical Research Holdings, LLC	SN: 97915045	N/A	May 1, 2023	Accel Research Sites Network
Clinical Research Holdings, LLC	SN: 97915043	N/A	May 1, 2023	